NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has announced that it will release its second quarter and year to date 2024 financial results on August 14, 2024, after market close. The results will be available via press release on the company's investor relations website.
Following the release, NRx Pharmaceuticals will host a conference call at 4:30 PM ET on the same day to discuss the financial results and provide a corporate update. Investors can access the call through a live webcast on the company's website or by dialing in using the provided domestic and international phone numbers.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), una società biofarmaceutica in fase clinica, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre e dell'anno fino ad oggi 2024 il 14 agosto 2024, dopo la chiusura del mercato. I risultati saranno disponibili tramite comunicato stampa sul sito web delle relazioni con gli investitori della società.
Dopo la pubblicazione, NRx Pharmaceuticals ospiterà una call conferenza alle 16:30 ET lo stesso giorno per discutere i risultati finanziari e fornire un aggiornamento aziendale. Gli investitori potranno accedere alla chiamata tramite un webcast dal vivo sul sito web della società o componendo i numeri di telefono nazionali e internazionali forniti.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), una compañía biofarmacéutica en etapa clínica, ha anunciado que dará a conocer sus resultados financieros del segundo trimestre y del año hasta la fecha 2024 el 14 de agosto de 2024, después del cierre del mercado. Los resultados estarán disponibles a través de un comunicado de prensa en el sitio web de relaciones con inversores de la compañía.
Tras la publicación, NRx Pharmaceuticals llevará a cabo una concferencia telefónica a las 4:30 PM ET el mismo día para discutir los resultados financieros y proporcionar una actualización corporativa. Los inversores podrán acceder a la llamada a través de un webcast en vivo en el sitio web de la compañía o llamando a los números de teléfono nacionales e internacionales proporcionados.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), 임상 단계 생명공학 회사,는 2024년 2분기 및 연초 재무 결과를 2024년 8월 14일 시장 종료 후 발표할 것이라고 발표했습니다. 결과는 회사의 투자자 관계 웹사이트에서 보도 자료를 통해 제공될 것입니다.
발표 이후 NRx Pharmaceuticals는 같은 날 오후 4:30 ET에 재무 결과를 논의하고 기업 업데이트를 제공하기 위해 컨퍼런스 콜을 개최합니다. 투자자들은 회사 웹사이트에서 라이브 웹캐스트를 통해 또는 제공된 국내 및 국제 전화번호로 전화를 걸어 접근할 수 있습니다.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), une entreprise biopharmaceutique en phase clinique, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre et de l'année à ce jour 2024 le 14 août 2024, après la fermeture du marché. Les résultats seront disponibles par le biais d'un communiqué de presse sur le site Web des relations avec les investisseurs de l'entreprise.
Après la publication, NRx Pharmaceuticals organisera une conférence téléphonique à 16h30 ET le même jour pour discuter des résultats financiers et fournir une mise à jour corporative. Les investisseurs peuvent accéder à l'appel via un webinaire en direct sur le site Web de l'entreprise ou en appelant les numéros de téléphone nationaux et internationaux fournis.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat bekannt gegeben, dass es seine Finanzergebnisse für das zweite Quartal und das Jahr bis heute 2024 am 14. August 2024 nach Marktschluss veröffentlichen wird. Die Ergebnisse werden über eine Pressemitteilung auf der Investor-Relations-Website des Unternehmens verfügbar sein.
Nach der Veröffentlichung wird NRx Pharmaceuticals am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Finanzergebnisse zu diskutieren und ein Unternehmensupdate zu geben. Investoren können auf die Konferenz über ein Live-Webcast auf der Website des Unternehmens zugreifen oder die bereitgestellten nationalen und internationalen Telefonnummern anrufen.
- None.
- None.
A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events . Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-second-quarter-and-year-to-date-2024-financial-results-on-august-14-2024-302221376.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
When will NRx Pharmaceuticals (NRXP) release its Q2 2024 financial results?
How can investors access NRXP's Q2 2024 earnings conference call?
Where can I find NRx Pharmaceuticals' (NRXP) Q2 2024 financial results?
